156 related articles for article (PubMed ID: 38474177)
81. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy.
Andrei G; Snoeck R
Curr Opin Infect Dis; 2015 Dec; 28(6):611-24. PubMed ID: 26524334
[TBL] [Abstract][Full Text] [Related]
82. KSHV MicroRNAs Repress Tropomyosin 1 and Increase Anchorage-Independent Growth and Endothelial Tube Formation.
Kieffer-Kwon P; Happel C; Uldrick TS; Ramalingam D; Ziegelbauer JM
PLoS One; 2015; 10(8):e0135560. PubMed ID: 26263384
[TBL] [Abstract][Full Text] [Related]
83. A KSHV microRNA Directly Targets G Protein-Coupled Receptor Kinase 2 to Promote the Migration and Invasion of Endothelial Cells by Inducing CXCR2 and Activating AKT Signaling.
Hu M; Wang C; Li W; Lu W; Bai Z; Qin D; Yan Q; Zhu J; Krueger BJ; Renne R; Gao SJ; Lu C
PLoS Pathog; 2015 Sep; 11(9):e1005171. PubMed ID: 26402907
[TBL] [Abstract][Full Text] [Related]
84. The Kaposi's Sarcoma-Associated Herpesvirus ORF34 Protein Interacts and Stabilizes HIF-2α via Binding to the HIF-2α bHLH and PAS Domains.
Haque M; Kousoulas KG
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189709
[TBL] [Abstract][Full Text] [Related]
85. miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA.
Lin X; Liang D; He Z; Deng Q; Robertson ES; Lan K
PLoS One; 2011 Jan; 6(1):e16224. PubMed ID: 21283761
[TBL] [Abstract][Full Text] [Related]
86. Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2.
Lee SM; Kaye KM; Slack FJ
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725152
[TBL] [Abstract][Full Text] [Related]
87. Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.
Hu M; Armstrong N; Seto E; Li W; Zhu F; Wang PC; Tang Q
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651359
[TBL] [Abstract][Full Text] [Related]
88. STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus.
King CA; Li X; Barbachano-Guerrero A; Bhaduri-McIntosh S
J Virol; 2015 Nov; 89(22):11347-55. PubMed ID: 26339061
[TBL] [Abstract][Full Text] [Related]
89. Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin β3 Levels and Is Dependent on STAT3.
Rivera-Soto R; Dissinger NJ; Damania B
J Virol; 2020 Feb; 94(5):. PubMed ID: 31801855
[TBL] [Abstract][Full Text] [Related]
90. Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.
Li S; Bai L; Dong J; Sun R; Lan K
Adv Exp Med Biol; 2017; 1018():91-127. PubMed ID: 29052134
[TBL] [Abstract][Full Text] [Related]
91. Cellular and viral oncogenes: the key to unlocking unknowns of Kaposi's sarcoma-associated herpesvirus pathogenesis.
Hussein HAM; Okafor IB; Walker LR; Abdel-Raouf UM; Akula SM
Arch Virol; 2018 Oct; 163(10):2633-2643. PubMed ID: 29936609
[TBL] [Abstract][Full Text] [Related]
92. Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNAs promote matrix metalloproteinases (MMPs) expression and pro-angiogenic cytokine secretion in endothelial cells.
Guo Y; Li W; Qin J; Lu C; Fan W
J Med Virol; 2017 Jul; 89(7):1274-1280. PubMed ID: 28165144
[TBL] [Abstract][Full Text] [Related]
93. The Expression and Nuclear Retention Element of Polyadenylated Nuclear RNA Is Not Required for Productive Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
Gutierrez IV; Dayton J; Harger S; Rossetto CC
J Virol; 2021 Jun; 95(13):e0009621. PubMed ID: 33853955
[TBL] [Abstract][Full Text] [Related]
94. Kaposi's sarcoma-associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection.
Gjyshi O; Bottero V; Veettil MV; Dutta S; Singh VV; Chikoti L; Chandran B
PLoS Pathog; 2014 Oct; 10(10):e1004460. PubMed ID: 25340789
[TBL] [Abstract][Full Text] [Related]
95. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation.
Lu J; Verma SC; Murakami M; Cai Q; Kumar P; Xiao B; Robertson ES
J Virol; 2009 Jul; 83(14):7129-41. PubMed ID: 19439469
[TBL] [Abstract][Full Text] [Related]
96. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays.
Dittmer DP
Cancer Res; 2003 May; 63(9):2010-5. PubMed ID: 12727810
[TBL] [Abstract][Full Text] [Related]
97. A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis.
Ma Q; Cavallin LE; Leung HJ; Chiozzini C; Goldschmidt-Clermont PJ; Mesri EA
Antioxid Redox Signal; 2013 Jan; 18(1):80-90. PubMed ID: 22746102
[TBL] [Abstract][Full Text] [Related]
98. Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy.
Li F; Cao D; Gu W; Li D; Liu Z; Cui L
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474177
[TBL] [Abstract][Full Text] [Related]
99. Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment.
Li F; Cao D; Yao L; Gu W; Liu Z; Li D; Cui L
Front Bioeng Biotechnol; 2023; 11():1343956. PubMed ID: 38260739
[TBL] [Abstract][Full Text] [Related]
100. miR-34a-5p inhibits the malignant progression of KSHV-infected SH-SY5Y cells by targeting c-fos.
Wu S; Wu Z; Xu H; Zhang J; Gu W; Tan X; Pan Z; Cao D; Li D; Yang L; Li D; Pan Y
PeerJ; 2022; 10():e13233. PubMed ID: 35444864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
